Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference
04 avr. 2024 18h34 HE
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., April 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Opthea Appoints Sujal Shah to the Board of Directors
03 avr. 2024 17h39 HE
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024
19 mars 2024 06h00 HE
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to...
Opthea to Participate in the Leerink Partners Global Biopharma Conference
05 mars 2024 17h08 HE
|
Opthea Limited
MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly...
Opthea Reports Half-Year Financial Results and Business Updates
28 févr. 2024 17h55 HE
|
Opthea Limited
Enrollment completion of sozinibercept Phase 3 program for wet AMD expected in calendar year (CY) Q2 2024 with top-line data mid-CY 2025 Expanded U.S. leadership team with the appointments of Dr....
Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor
19 févr. 2024 18h25 HE
|
Opthea Limited
MELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT, “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly...
Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept
14 févr. 2024 07h00 HE
|
Opthea Limited
COAST trial is evaluating the superiority of sozinibercept combined with EYLEA® (aflibercept) over EYLEA alone in wet AMD Enrollment of second pivotal trial (ShORe) to complete in calendar Q2 2024 ...
Opthea Strengthens Team with Key Clinical and Regulatory Hires
01 févr. 2024 06h00 HE
|
Opthea Limited
Dr. Julie Clark, SVP Clinical Development; Dr. Fang Li, SVP Regulatory Affairs, to join February 1stExperienced executives bring extensive track record in products for retinal and ophthalmology...
Opthea to Receive US$35M Commitment and Additional US$50M Funding
27 déc. 2023 06h00 HE
|
Opthea Limited
Opthea to receive remaining US$35m funding under the Development Funding Agreement (DFA) with Carlyle and its life science franchise Abingworth, as well as a further US$50m financing under an Amended...
Opthea Receives A$8.8 million R&D Tax Incentive
19 déc. 2023 06h00 HE
|
Opthea Limited
MELBOURNE, Australia, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...